Shareholders’ Nomination Board | 05-Nov-2024 | 07:00 | RNS |
Faron’s Capital Markets Day 2024 | 22-Oct-2024 | 07:00 | RNS |
Grant of options | 30-Aug-2024 | 07:00 | RNS |
Faron 2024 Half-Year Financial Results | 27-Aug-2024 | 07:00 | RNS |
FDA Grants Fast Track Designation for Bexmarilimab | 27-Aug-2024 | 07:00 | RNS |
Notice of Half-Year Financial Results | 20-Aug-2024 | 07:00 | RNS |
Appointment of Chief Financial Officer | 08-Aug-2024 | 07:00 | RNS |
Grant of options | 07-Aug-2024 | 10:00 | RNS |
Faron Appoints Dr. Petri Bono as new CMO | 06-Aug-2024 | 08:30 | RNS |
Faron Announces Positive FDA Feedback | 11-Jul-2024 | 07:00 | RNS |
Update on settlement | 25-Jun-2024 | 14:00 | RNS |
Holding(s) in Company - Replacement | 25-Jun-2024 | 10:30 | RNS |
Holding(s) in Company | 24-Jun-2024 | 12:45 | RNS |
Holding(s) in Company | 24-Jun-2024 | 12:45 | RNS |
Holding(s) in Company | 24-Jun-2024 | 12:45 | RNS |
Currency | UK Pounds |
Share Price | 142.50p |
Change Today | -5.00p |
% Change | -3.39 % |
52 Week High | 350.00p |
52 Week Low | 92.50p |
Volume | 6,706 |
Shares Issued | 104.62m |
Market Cap | £149.09m |
Beta | 1.67 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 1 |
Buy | 1 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 1 |
Total | 3 |
No dividends found |
Time | Volume / Share Price |
16:04 | 1,000 @ 143.50p |
15:48 | 130 @ 140.00p |
15:39 | 340 @ 143.50p |
15:38 | 688 @ 143.50p |
15:26 | 1,550 @ 144.50p |
CFO | Yrjö E K Wichmann |
CEO | Juho Jalkanen |
Chair | Tuomo Pätsi |
You are here: research